The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
Together, these studies support further investigation of GZD824 as a potential therapeutic agent in endometrial cancer, potentially in combination with immune checkpoint inhibitors.
Authors
- Dylan M. Glubb
- Caroline E. Ford (ORCID: https://orcid.org/0000-0002-4438-2309)
- Tracy A. O’Mara (ORCID: https://orcid.org/0000-0002-5436-3232)
- Dongli Liu (ORCID: https://orcid.org/0000-0002-1755-8516)
Institutions
- QIMR Berghofer Medical Research Institute (AU)
- UNSW Sydney (AU)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1002/cam4.70531
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- University of New South Wales
- Medical Research Council
- National Health and Medical Research Council